Product News and Recalls

Report says Yaz, Yasmin big money-makers for Bayer

Shannon Pettypiece of Bloomberg Television provides some context for the recent national debates about birth control, pointing out that birth control constitutes “big business for big pharma.”

In a recent report, Ms. Pettypiece observed that Americans spent $5 billion last year for birth control. She said the German corporation Bayer gets about $1.5 billion a year from its drugs Yaz and Yasmin.

See the video here:

http://www.bloomberg.com/video/87718882/

Several studies show that Yaz, Yasmin, continue reading...

Yaz/Beyaz maker Bayer considering “significant” aquisition

Bayer, the German corporation that manufactures birth control pills Yaz, Beyaz and Yasmin, could finance a “significant” acquisition using a combination of debt, equity and its portfolio assets, Bloomberg reports.

Bloomberg cites an interview with Bayer’s Chief Financial Officer Werner Baumann, who said the company would only sell one of its three units “on the merits of its own strategic assessment.”

“You will not find us in a situation where we say we want to buy this, therefore we have to sell ...

continue reading...

British surgeons: Ban metal-on-metal hip joints

The British Hip Society, consisting of surgeons and scientists who work with the hip joint, has issued a recommendation that the use of metal-on-metal hip implants be discontinued because of their high early failure rate.

The Daily Telegraph quotes Joe Dias, president of the British Orthopaedic Association, as saying that about 5.5 percent of the large metal-on-metal implants – in which the ball and the socket are both coated with metal — needed to be replaced because of wear-and-tear within five ...

continue reading...

Frequent, long-term monitoring recommended for hip implants

According to an article in the New York Times, British health regulators are recommending that patients who received a certain type of metal-on-metal hip implant get annual examinations for as long as they have the devices, because of concerns that the implants will shed pieces of metallic debris as they wear.

Previously, the health regulators had recommended that the patients be monitored for five years. But recent data show the hip implants in question – consisting of both a ball and ...

continue reading...

Formulation with controversial compound approved

The federal Food and Drug Administration has approved a new, lower-dose formulation of a Bayer corporation drug used to treat menopausal symptoms.

The drug Angeliq contains drospirenone, a synthetic progestogen that may elevate the levels of potassium in the body.

“We are pleased by the approval of this important new lower-dose option for menopausal women,” Bayer HealthCare Pharmaceuticals VP and head of U.S. medical affairs Pamela Cyrus said. “The availability of the new lower dose of Angeliq supports current guidelines which recommend ...

continue reading...

Journalist: Women should be aware of Yaz/Beyaz risks

A recent piece in the magazine “Ms.” by journalist Holly Grigg-Spall urges more women to educate themselves about potential health risks concerning the birth control pills Yaz and Beyaz, manufactured by German corporation Bayer.

Ms. Grigg-Spall points out that Yaz became the most popular birth control pill in the U.S. soon after its release in 2006, as the result of a marketing campaign that the federal Food and Drug Administration subsequently ruled to be misleading. The FDA requested that Bayer run ...

continue reading...
Page 308 of 323 «...280290300306307308309310...»